SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Metrics to compare | SQZB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSQZBPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −3.0x | −0.6x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 0.0x | 1.2x | 2.6x | |
Price / LTM Sales | 0.0x | 8.7x | 3.3x | |
Upside (Analyst Target) | 0.0% | 206.0% | 39.5% | |
Fair Value Upside | Unlock | 1.9% | 4.9% | Unlock |